

Anti-NCAM1/CD56 Antibody (Lorvotuzumab)

Introduction

Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a CD56 (NCAM1) Lorvotuzumab can be used to synthesize the ADC compound Lorvotuzumab mertansine.

Product parameters

Alternative Names	Lorvotuzumab
Target Accession	P13591
Target	NCAM1 / CD56
CAS number	/
Molecular Weight	146.44 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	TT Cell Line were stained with Anti-NCAM1/CD56 Antibody (Lorvotuzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 0.015 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

